Biogen Inc. (NASDAQ: BIIB) is a pioneering American biotechnology company headquartered at 225 Binney Street, Cambridge, Massachusetts. Founded in 1978 by Nobel laureates Walter Gilbert and Phillip Sharp, Biogen has established itself as a global leader in neuroscience and rare disease therapies.
Company Overview
Headquarters: Cambridge, MA (planning to move to 75 Broadway in 2028)
Founded: April 14, 1978 in Geneva, Switzerland (relocated to Cambridge in 1982)
Employee Count: 7,605 as of December 31, 2024 (+0.46% from 2023)
Public Company: Listed on NASDAQ
Revenue Mix by Segment (2025)
2025 Revenue Composition ($9.9B Total)
Revenue Growth Trajectory (2020-2026F)
Total Revenue Trend & Forecast
Strategic Position
Biogen is undergoing a strategic transformation from legacy multiple sclerosis (MS) treatments to a diversified portfolio emphasizing rare diseases and neurological conditions. Under CEO Christopher Viehbacher (appointed November 2022), the company is executing its "Fit for Growth" cost optimization program targeting ~$1 billion in gross savings by end-2025, while simultaneously investing in pipeline expansion through business development.
Growth Products (including LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY, and VUMERITY) generated $3.3 billion in 2025 revenue (+19% YoY), offsetting legacy MS portfolio declines. The company's transformation is evident in its product mix: 45% of revenue now comes from non-MS medicines, with 55% of product revenue from outside the U.S.
Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.
Company History
Founding and Early Years (1978-1989)
Biogen was founded on April 14, 1978, in Geneva, Switzerland, initially as Biotechnology Geneva (Biogen NV) by a distinguished group of scientists pioneering recombinant DNA technology:
Walter Gilbert (Nobel laureate, first CEO)
Charles Weissmann
Heinz Schaller
Kenneth Murray
Phillip Allen Sharp (Nobel laureate)
In 1982, Biogen relocated its headquarters to Cambridge, Massachusetts. The company went public with its IPO in 1983. The early years were financially precarious, with James L. Vincent becoming CEO in 1985, averting bankruptcy after the company accumulated $100 million in losses. By 1989, Biogen achieved its first profit of $3.2 million on $28.5 million in sales.
Biogen Idec Merger (2003)
On November 12, 2003, Biogen merged with Idec Pharmaceuticals to form Biogen Idec, a transformational deal that expanded the company's focus to include oncology and neurology. In 2015, the company was renamed to Biogen Inc.
Strategic Acquisitions
2006: Acquired Conforma Therapeutics for $250 million
2007: Licensed Aducanumab for Alzheimer's from Neurimmune
2023: Acquired Reata Pharmaceuticals (SKYCLARYS for Friedreich's ataxia)
2024: Completed $1.15 billion acquisition of HI-Bio for felzartamab
2025: Partnership with Stoke Therapeutics for zorevunersen (Dravet syndrome)
Ownership Structure
Biogen Inc. is a publicly traded company listed on the NASDAQ under ticker symbol BIIB. Institutional ownership represents 87.93% of outstanding stock, with approximately 1,189 institutional owners holding around 142 million shares.
Top Institutional Shareholders
Shareholder
Value/Shares
Ownership %
Vanguard Group Inc.
~$2.17 billion
Top holder
BlackRock, Inc.
Not disclosed
Second largest
Primecap Management Co.
$1.98B / 14.95M shares
~10.20%
State Street Corp
$938M / 7.32M shares
~5.00%
FMR LLC (Fidelity)
9.41M shares
6.40%
Board of Directors
Board Chair transition scheduled for June 9, 2026: Maria C. Freire, M.D., Ph.D. succeeds Caroline Dorsa as Chair. Key independent directors include Eric Rowinsky, William Hawkins, Stephen Sherwin, Jesus Mantas (Compensation Committee Chair), and Lloyd Minor (Audit Committee).
Leadership / C-Suite
Executive
Title
Start Date
Christopher Viehbacher
President & CEO
November 2022
Robin Kramer
EVP & CFO
February 2025
Priya Singhal, M.D.
EVP, Head of Development
2020
Alisha Alaimo
President, Head of North America
2017
Nicole Murphy
EVP, Pharmaceutical Operations
2015
Susan Alexander
Chief Legal Officer
20.2 years tenure
Drug Portfolio
Neuroscience / Multiple Sclerosis Portfolio
Product
Indication
Revenue (2025)
Growth
Patent Status
TYSABRI
Relapsing MS
~$1,573M (projected)
Declining
US patents expire 2026-2027
TECFIDERA
Relapsing MS
Not disclosed
Declining
Generic competition
VUMERITY
Relapsing MS
Included in $3.3B growth
Growing (+19% YoY)
Protected
LEQEMBI
Alzheimer's disease
$87M Q4 '24; $96M Q1 '25
Growing (+395% YoY)
Protected (co-marketed Eisai)
ZURZUVAE
Postpartum depression
$22M Q3 '24 (total)
Growing gradually
Protected (co-marketed Sage/Supernus)
Rare Disease / Neuromuscular Portfolio
Product
Indication
Revenue (2025)
Growth
Peak Sales Potential
SPINRAZA
Spinal muscular atrophy
$356M Q4 '25; FY -2% YoY
Declining
Past peak (~$2B)
SKYCLARYS
Friedreich's ataxia
$124M Q1 '25
Strong growth
$500M-1B
QALSODY
SOD1-ALS
$533M Q2 '25 (segment)
Growing
$300-500M
Top 5 CEO Focus Drugs
Based on earnings calls and strategic communications, CEO Christopher Viehbacher emphasizes:
QALSODY (tofersen) - SOD1-ALS; precision medicine flagship despite small population
SPINRAZA (nusinersen) - SMA; HD-SPINRAZA positioned to recapture market share; FDA decision April 3, 2026
VUMERITY (diroximel fumarate) - MS oral; sustaining franchise amid genericization
R&D Pipeline
Biogen has 10 Phase 3 trials underway with multiple readouts expected in 2026-2027, characterized by CEO as "the year where we start to turn over the cards."
Program
Indication
Expected Readout
Partnership
Litifilimab
Cutaneous lupus
Phase 2: End Q1 2026
Proprietary (FDA Breakthrough)
Litifilimab
Systemic lupus
Phase 3: Q4 2026
Proprietary
Felzartamab
Kidney diseases
Phase 3: Mid-2027
HI-Bio ($1.15B acquisition)
Zorevunersen
Dravet syndrome
Phase 3: Mid-2027
Stoke Therapeutics
HD-SPINRAZA
Spinal muscular atrophy
FDA decision: April 3, 2026
Proprietary
Competitive Landscape
Multiple Sclerosis
Major Competitors: Novartis, Roche, Sanofi, Merck KGaA, Teva, BMS, AbbVie, Janssen. Over 75 companies and 80 pipeline therapies in development. Key threats: biosimilar TYSABRI (post-2026 patent expiry), high-efficacy anti-CD20 therapies (Ocrevus, Kesimpta), BTK inhibitors.
Alzheimer's Disease
Major Competitor: Eli Lilly (donanemab). Market constrained by infusion requirements, ARIA monitoring, reimbursement hurdles. LEQEMBI differentiation: full FDA approval, robust Phase 3 data, Eisai geographic reach.
Spinal Muscular Atrophy
Major Competitors: Novartis ZOLGENSMA (one-time gene therapy, $2.1M), Roche Evrysdi (oral). SPINRAZA retains advantage in late-onset SMA (Types 2/3) and markets with limited gene therapy infrastructure.
Risks and Challenges
Patent Cliff: TYSABRI patents expire 2026-2027; biosimilar entry expected to accelerate MS franchise decline
Competitive Pressure: 75+ companies in MS; ZOLGENSMA eroding SPINRAZA; donanemab competing with LEQEMBI
Total Revenue: Mid-single-digit percentage decline vs. 2025 ($9.9B)
Non-GAAP Diluted EPS: $15.25-$16.25
Drivers: Continued MS decline offset by growth products (LEQEMBI, SKYCLARYS, QALSODY)
Peer Comparison
Company
Market Cap
2025 Revenue
Focus
Biogen
$27-28B
$9.9B
Neuroscience, rare disease
Vertex
~$120B
~$10B+
Cystic fibrosis, gene editing
Regeneron
~$100B
~$13B+
Ophthalmology, immunology
Gilead
~$100B
~$27B
HIV, HCV, oncology
Investment Thesis: Biogen's valuation reflects investor concerns about MS patent cliff, but successful execution of "bridge to growth" strategy (10 Phase 3 readouts 2026-27, LEQEMBI inflection, rare disease expansion) could drive re-rating. Bull case: Pipeline successes + LEQEMBI acceleration = revenue growth resumption by 2027-28. Bear case: Pipeline failures + LEQEMBI stagnation + accelerated MS erosion = sustained revenue decline.
Ada Patient Finder Analysis
Perfect Fit: SKYCLARYS (Friedreich's Ataxia)
Ada Fit Score: 10/10 ⭐⭐⭐
Diagnostic Delay: Median 3 years (IQR: 1-7 years); Brazilian study mean 7.8 ± 6.7 years, consulting 6.2 ± 4.1 physicians.
Underdiagnosis: 30-50% estimated (especially late-onset FRDA >25 years presenting without classic features).
Net Revenue Per Patient: $148,000-222,000/year (U.S. net after 40-60% gross-to-net adjustment).
Ada Symptom Surfacing: Excellent. Gait ataxia, coordination issues, slurred speech, balance problems, scoliosis, and cardiomyopathy are all capturable via symptom assessment.
Pitch Hook: "Friedreich's ataxia patients endure a median 3-year diagnostic odyssey (mean 7.8 years in some cohorts), consulting 6+ physicians as gait ataxia, slurred speech, and coordination deficits are misattributed to cerebral palsy, MS, or nonspecific neurological disorders. 30-50% remain undiagnosed, especially late-onset cases. Ada's symptom assessment excels at surfacing ataxia patterns – progressive balance loss, dysarthria, absent reflexes, cardiac red flags (hypertrophic cardiomyopathy) – prompting FXN genetic testing. With ~2,000-4,000 undiagnosed U.S. patients and net revenue of $148K-222K per patient annually, Ada Patient Finder could identify 1,000-2,000 SKYCLARYS candidates, generating $148M-444M in first-year revenue expansion while transforming lives before irreversible disability and cardiac complications progress. SKYCLARYS is first-and-only approved FRDA therapy – capturing undiagnosed patients is pure market expansion."
Strong Fit: SPINRAZA (SMA Type 3/Adult-Onset)
Ada Fit Score: 8/10
Diagnostic Delay: SMA Type 3 median 11.37 months; patients visit 3.94 doctors before diagnosis.
Underdiagnosis: 20-30%, especially Type 3 and adult-onset.
Net Revenue Per Patient: $300,000-450,000 first year; $150,000-225,000 ongoing (U.S. net).
Ada Symptom Surfacing: Moderate. Progressive weakness, gait disturbance, scoliosis surface in Ada, but SMA requires genetic testing.
Pitch Hook: "SMA Type 3 patients face a median diagnostic delay of 11.37 months and consult nearly 4 physicians before genetic confirmation. Progressive muscle weakness, gait abnormalities, and scoliosis are often misattributed to orthopedic or neurological conditions. Ada's symptom assessment can flag rare neuromuscular patterns and prompt SMN1 genetic testing referrals, capturing the 20-30% of undiagnosed SMA patients (estimated 2,000-5,000 in the U.S.). At $300K-450K net revenue per patient in the first year, identifying just 500 patients would generate $150M-225M in incremental revenue for SPINRAZA."
Summary Table: Ada Patient Finder Fit Scores
Drug
Indication
Diagnostic Delay
Net Revenue/Pt/Yr
Fit Score
Recommendation
SKYCLARYS
Friedreich's ataxia
3-7.8 years
$148K-222K
10/10
HIGHEST PRIORITY
SPINRAZA
SMA Type 3
11.37 months
$300K-450K first yr
8/10
STRONG FIT
TYSABRI
Multiple sclerosis
2-14 months
$32K-60K
7/10
MODERATE (patent cliff 2026-27)
ZURZUVAE
Postpartum depression
57.4% late-onset missed
$6.4K-9.5K one-time
6/10
NO (revenue too low; alternative: awareness campaign)